Page 73 - MEMOCiberesp014-ENG

Most relevant scientific articles
• Benito M.J., gonzÁlez-garCía M.J., teson M., garCía n., FernÁnDez i., Calonge M. et al . Intra- and inter-day variation of cytokines and chemokines in tears of healthy subjects . Experimental Eye Research . 2014; 120:43-49 .
• lóPez-Miguel a., teson M., Martín-MontÁnez V., enríquez-De-salaManCa a., stern M.e., Calonge M. et al . Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental condi- tions . American Journal of Ophthalmology . 2014;157(4) .
• arranz-Valsero i., soriano-roMani l., garCía-PosaDas l., lóPez-garCía a., DieBolD y. IL-6 as a corneal wound healing mediator in an invitro scratch assay . Experimental Eye Research . 2014; 125:183-192 .
• Martín-MontÁnez V., lóPez-Miguel a., arroyo C., Mateo M.e., gonzÁlez-MeiJoMe J.M., Calonge M. et al . In- fluence of environmental factors in the in vitro dehydration of hydrogel and silicone hydrogel contact lenses . Journal of Biomedical Materials Research - Part B Applied Biomaterials . 2014; 102(4):764-771 .
• garCía-PosaDas l., Contreras-ruiz l., arranz-Valsero i., loPez-garCia a., Calonge M., DieBolD y. CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation . Graefe’s Archive for Clinical and Experimental Ophthalmology . 2014;252(8):1289-1295 .
Highlights
Institution: Universidad de Valladolid Contact: Instituto de Oftalmobiología Aplicada . Campus Univ . Miguel Delibes . C/ del Cementerio, s/n . 47011 Valladolid · Teléfono: (+34) 983 184 750 · E-mail: calonge@ioba .med .uva .es
PROYECTOS INTRAMURALES
• BioScaff-EYE: “Bio-engineered stem cell niches in ocular surface reconstruction for corneal blindness: from basic research to clinical trials”, coordinated by IOBA-UVa was transferred to Ferrer Advan- ced Biotherapeutics (FAB) . Three groups: IOBA-UVa, Valladolid (PI M .Calonge), IBEC-Barcelona (PI E .Engel), and NanoBioCel (PI JL .Pedraz), are closely working with CIBER-BBN and FAB to lead this project to the desired end at maximum speed . As a result in vitro studies concluded and animal stu- dies were well advanced in 2014, and the project is ready to apply for a POC clinical trial along 2015 . Additionally, IOBA-UVa finished in 2014 the first double-masked randomized clinical trial to report safety and efficacy of mesenchymal stem cells (MSC) in human ocular surface . The positive results of this trial facilitate immensely the clinical translation of this project . Due to the signed non-disclosure agreement, dissemination of results is not yet allowed . Patents are being prepared but not released during 2014 .
• EYE-PoC: “Point-of-care biosensor devices to detect biomarkers as evaluation end-points for thera- peutic clinical trials in ocular surface inflammation” was granted in 2014 . It’s coordinated by IOBA- UVa, the clinical group (PI A . Enríquez-de-Salamanca) and teamed with NB4D-CISC (PI R . Galve, E . Valera), CIN2-CISC (PI L . Lechuga) and GQNA-CISC (PI A . Aviñó) . During 2014, a selection of 4 can- didate molecules to be placed in PoC devices was possible by analyzing a broad database of previous clinical studies . Time to disseminate results has been insufficient .
• NANO-OPHTHAL: “New si-RNA-nanoparticle conjugates for the treatment of ocular surface inflam- mations”, granted as “excelent project” during 2014, is coordinated by Nanomol-CISC (PI S . Sala/ J . Veciana) and teamed with GDAB-UAH (PI J .de-la-Mata), GQNA-CISC (PI R . Eritja), IOBA-UVa as clinical group (PI M . Calonge) and external group (R . Herrero) . Experimental work has just begun trying to conjugate siRNA targeting TNFalpha using tears . Time to disseminate results has been insufficient .
www .ciber-bbn .es 73